- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04585893
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Matthew Painschab, MD
- Phone Number: 763 234 5055
- Email: matthew.painschab@unchealth.unc.edu
Study Locations
-
-
-
Lilongwe, Malawi
- Recruiting
- UNC Project, Kamuzu Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newly diagnosed or previously treated subjects with KSHV-associated MCD that is pathologically confirmed by characteristic histologic features and latency-associated nuclear antigen (LANA) positivity by Immunohistochemistry (IHC).
- Age is greater than or equal 18 years old at time of consent.
- Can provide informed consent.
- HIV-infected or HIV-uninfected.
- If HIV-infected, must be on or willing to start antiretroviral therapy including lamivudine or tenofovir.
- Willing to comply with study visits.
MCD treatment indicated based on the presence of a symptomatic MCD flare, defined as the presence of each of the following three criteria:
- Fever (subjective or objective)
- Lymphadenopathy or hepatosplenomegaly
At least one of the following signs or symptoms attributable to MCD by the local study investigator:
- Weight loss >5%
- Malaise
- Anemia (Hemoglobin <10 g/dL) within the past 4 weeks
- Thrombocytopenia (Platelets <100 x 103/mL) NOTE: If only two of the three criteria are present, but the provider feels treatment is indicated for a symptomatic MCD flare, this will be allowed after communication with the study principal investigator (PI).
Subjects with low hemoglobin within the past 4 weeks that have since received a blood transfusion are still eligible for participation. The subject's pre-transfusion hemoglobin value will be considered when determining risk classification.
Females of childbearing potential must have a negative urine pregnancy test within three days prior to registration.
NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided.
- Females must agree to abstain from breastfeeding during therapy and for 6 months after the completion of therapy.
- Females of childbearing potential must be willing to abstain from heterosexual activity or to use two forms of effective methods of contraception from the time of informed consent until 12 months after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, a barrier method plus a hormonal method, or an intrauterine device that meets <1% failure rate for protection from pregnancy in the product label.
- Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 6 months after the last dose of study therapy.
- More than 7 days without corticosteroid use prior to starting the treatment.
Exclusion Criteria:
- Symptomatic, extensive-stage KS (T1 by the AIDS Clinical Trials Group (ACTG) staging system; T1 includes ulceration or edema from KS, raised or non-hard palate oral lesions, or any visceral involvement) requiring urgent treatment, to avoid potential rituximab-induced KS worsening.
- Previous rituximab use for MCD.
- Second active malignancy requiring systemic therapy.
- If HIV negative and a) hepatitis B virus surface antigen positive or b) a combination of HepB core antibody positive and HepB surface antibody negative (indicative of chronic infection) unless on tenofovir or lamivudine. All HIV-infected patients must be on tenofovir or lamivudine as part of the inclusion criteria.
- Active infection requiring systemic therapy.
- Treatment with any investigational drug within 28 days prior to registration.
- More than 7 days of corticosteroids immediately prior to enrollment. If the subject is taking corticosteroids for more than 7 days, they require a 7 day washout period before enrollment.
- Bilirubin >3 mg/dL.
- Creatinine clearance <30 ml/min by Cockcroft-Gault formula.
- ECOG performance status >3.
- Pregnant or breastfeeding (Note: Breast milk cannot be stored for future use while the mother is being treated in the study).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm Rituximab
The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually. High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2). Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone. |
375 mg/m^2 administered via IV infusion weekly for four weeks.
Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
Other Names:
Subjects with high-risk disease will receive 100 mg/m^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of MCD presentation in Malawi
Time Frame: Baseline - until 21 days
|
Characterization of Multicentric Castleman disease (MCD) presentation in Malawi will be summarized using baseline demographics and laboratory values.
Descriptive statistics (means, median, variability measure for continuous variables, rates, and proportion for binary variables) will be performed.
|
Baseline - until 21 days
|
the rate of total non-hematologic Grade ≥3 adverse events (AEs)
Time Frame: From the start of rituximab-based therapy to 12 weeks. (Up to 13 weeks)
|
Safety will be assessed as the rate (percentage) of total non-hematologic Grade ≥3 adverse events (AEs) and treatment-related mortality. AEs will be evaluated using National Cancer Institute's Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). The CTCAE grading (severity) scale is provided for each AE term/symptom: Grade 1 (Mild; asymptomatic); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE). |
From the start of rituximab-based therapy to 12 weeks. (Up to 13 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hemoglobin measurement
Time Frame: Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Hemoglobin will be measured in grams per deciliter (g/dL) at baseline, day 15, and end-of-treatment.
Differences will be compared by paired t-test.
|
Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Change in platelet count measurement
Time Frame: Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Platelet count will be measured in microliters (µl) at baseline, day 15, and end-of-treatment.
Differences will be compared by paired t-test.
|
Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Change in C-reactive protein measurement
Time Frame: Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
C-reactive protein (CRP) will be measured in milligrams per milliliter (mg/mL) at baseline, day 15, and end-of-treatment.
Differences will be compared by paired t-test.
|
Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Change in Kaposi sarcoma herpesvirus viral load measurement
Time Frame: Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Kaposi sarcoma herpesvirus (KSHV) viral load will be measured in copies per milliliter (copies/mL) at baseline, day 15, and end-of-treatment.
Differences will be compared by paired t-test.
|
Baseline, Day 15 and End of treatment (approximately 6 weeks)
|
Overall survival
Time Frame: 90 days, 1 year, and 2 years
|
Overall survival is the measure of time from the first treatment day to the date of death for any cause.
Subjects who have not had an event will be censored at the date of the last assessment documenting the subject was alive.
|
90 days, 1 year, and 2 years
|
Event-free survival
Time Frame: 90 days, 1 year, and 2 years
|
Event-free survival is the measure of time after treatment during which no sign of cancer (refractory disease, relapse, non-Hodgkin lymphoma development, or death ) is found.
|
90 days, 1 year, and 2 years
|
Efficacy of risk-adjusted treatment
Time Frame: At the end of the treatment, 12 weeks after start of the treatment
|
The efficacy of risk-adjusted treatment will be defined as the clinical response rate which is the resolution of presenting signs/symptoms that defined the Multicentric Castleman disease (MCD) attack.
MCD attack/flare is defined as the presence of each of the following three criteria: 1) Fever (subjective or objective), 2) Lymphadenopathy or hepatosplenomegaly, 3) At least one of the following signs or symptoms attributable to MCD by the local study investigator: a) Weight loss >5%, b) Malaise, c) Anemia (Hemoglobin <10 g/dL), and d) Thrombocytopenia (Platelets <100 x 10^3/uL).
|
At the end of the treatment, 12 weeks after start of the treatment
|
Clinical and Radiological Response Rate
Time Frame: At the end of the treatment, 12 weeks after start of the treatment
|
Clinical and Radiological Response Rate will be defined as the percentage of subjects without relapse defined using chest radiography, abdominal sonography, and physical exam for gross lymphadenopathy. Response criteria for lymph node response will be Complete response (CR)- the disappearance of all evident disease; Partial response (PR)-at least a 50% decrease in target lesions with no increase in non-target lesions, Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD); PD- the appearance of a new lesion or at least a 50% increase in lesion size. |
At the end of the treatment, 12 weeks after start of the treatment
|
Additional Safety
Time Frame: First day of the treatment through 12 weeks (Up to 13 weeks)
|
Additional Safety will be defined as all Adverse Events occurred.
AEs will be evaluated using National Cancer Institute's Common Terminology Criteria for Adverse Events version 5 (CTCAE v5).
|
First day of the treatment through 12 weeks (Up to 13 weeks)
|
The rate of Kaposi sarcoma exacerbation
Time Frame: Up to 2 years
|
The rate of Kaposi sarcoma exacerbation will be determined by symptomatic or clinical (dermatologic or visceral organ) exacerbation of the disease.
All disease flares will be biopsy confirmed whenever possible.
|
Up to 2 years
|
Quality of Life- patient-reported outcomes questionnaires
Time Frame: Baseline, week3, end of the treatment, 12 weeks, 6 months after the treatment, 24 months after the treatment, time of relapse.
|
Quality of Life- patient-reported outcomes (PRO) questionnaires will be assessed by the Patient-Reported Outcomes Measurement Information System Global Health Survey (PROMIS Global-10).
The survey includes 10 items about mental and physical health rated on Likert scales ranging from 1 to 5, with higher scores indicative of better health.
|
Baseline, week3, end of the treatment, 12 weeks, 6 months after the treatment, 24 months after the treatment, time of relapse.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Matthew Painschab, MD, University of North Carolina
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Castleman Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Etoposide
- Rituximab
Other Study ID Numbers
- LCCC 1950
- K01TW011470 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multicentric Castleman Disease
-
University of PennsylvaniaRecruitingCastleman Disease | Castleman's Disease, MulticentricUnited States
-
Peking Union Medical College HospitalUnknownMulticentric Castleman DiseaseChina
-
EusaPharma (UK) LimitedTerminatedIdiopathic Multicentric Castleman's DiseaseUnited States
-
EusaPharma (UK) LimitedUniversity of Sheffield (ScHARR); KMC Health Care; Castleman Disease Collaborative...Not yet recruitingIdiopathic Multicentric Castleman's Disease
-
National Cancer Institute (NCI)CompletedCastleman Disease | Multicentric Castleman Disease | Giant Lymph Node HyperplasiaUnited States
-
Beijing VDJBio Co., LTD.RecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingZanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial (iMCD)Idiopathic Multicentric Castleman's DiseaseChina
-
Peking Union Medical College HospitalRecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Hoffmann-La RocheCompleted
-
National Cancer Institute (NCI)WithdrawnPrimary Effusion Lymphoma | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States